This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 132.4% upside potential for Stoke Therapeutics (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 613.51% and 1,391.01%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Doximity Q4 Earnings Likely to Reflect Strong Product Momentum
by Zacks Equity Research
Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth.
BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut
by Zacks Equity Research
Biogen reports mixed first-quarter 2025 results. It also lowers its EPS guidance for the current year.
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
CG Oncology, Inc. (CGON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Biogen Keep the Beat Streak Alive This Earnings Season?
by Zacks Equity Research
In the first quarter, lower sales of BIIB's multiple sclerosis drugs are likely to have been offset by revenues from new drugs.
Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Stoke Therapeutics (STOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Stoke Therapeutics (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 64.71% and 483.59%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Argenx (ARGX) Surges 4.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
ChromaDex (CDXC) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ChromaDex (CDXC) delivered earnings and revenue surprises of 50% and 7.47%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength?
by Zacks Equity Research
Stoke Therapeutics (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in STOK now may turn out to be a prudent move.
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
by Zacks Equity Research
ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex are part of the Zacks top Analyst Blog.
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
by Zacks Equity Research
Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025.
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to Stoke Therapeutics' zorevunersen for the treatment of Dravet syndrome. Stock rises.
Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 66.8% in Stoke Therapeutics (STOK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 9.62% and 41.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 19.30% and 45.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?